https://orcid.org/0000-0002-4892-3563
References
- O'Hara DM , TheobaldV, ClementsEgan Aet al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. AAPS J.14, 316–328 (2012).
- King LE , FarleyE, ImazatoMet al. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team. AAPS J.16, 504–515 (2014).
- Geist BJ , ClementsEgan A, YangT, DongY, ShankarG. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management. Bioanalysis5(2), 227–244 (2013).
- Staack RF , StrackeOJ, StubenrauchK, VogelR, SchleypenJ, PapadimitriouA. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalyses should know about their reagents. Bioanalysis3(5), 523–534 (2011).
- O'Hara DM , TheobaldV. Life cycle management of critical ligand-binding reagents. Bioanalysis5(21), 2679–2696 (2013).
- Nowatzke W , WoolfE. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J.9, E117–E122 (2007).
- Piccoli S , MehtaD, VitalitAet al. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62). Bioanalysis11(24), 2207–2244 (2019).
- Duo J , BrunoJ, PiccoliS, DeSilvaB, ZhangYJ. Characterization of labeled reagents in ligand-binding assays by a surface plasmon resonance biosensor. Bioanalysis9(2), 193–207 (2017).
- Pihl S , Wavan der Strate B, GolobMet al. EBF recommendation on practical management of critical reagents for PK ligand-binding assays. Bioanalysis10(19), 1557–1565 (2018).
- Rocha AG , KrynskiK, MancinoA, SciscioneM, BeaverCJ. New insights on critical reagent optimization for antidrug antibody assays. Bioanalysis11(9), 815–823 (2019).
- Eangoor P . A guided approach to preclinical bioanalysis of proteins using immunoassays for pharmacokinetic and pharmacodynamic assessments. Bioanalysis12(16), 1105–1110 (2020).
- Zhang D , YangC, ChenX, LiX, ZhongD. A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222. Bioanalysis10(14), 1115–1127 (2018).
- Xiang Y , ParngC, OlsonK. Neutralizing antibody assay development with high drug and target tolerance to support clinical development of an Anti-TFPI Therapeutic monoclonal antibody. AAPS J.21, 46 (2019).
- Razinkov VI . Methods of high throughput biophysical characterization in biopharmaceutical development. Curr. Drug Discov. Technol.10(1), 59 (2013).
- Zhang Z , PanH, ChenX. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom. Rev.28(1), 147–176 (2009).
- Zhang Z . Large-scale identification and quantification of covalent modifications in therapeutic proteins. Anal. Chem.81(20), 8354–8364 (2009).
- Chirino AJ , Mire-SluisA. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol.22(11), 1383–1391 (2004).
- Haulenbeek J , PiccoliSP. Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance. Bioanalysis6(7), 983–992 (2014).
- Chen Y . Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. Methods Mol. Biol.1045, 267–273 (2013).
- Compendium of Chemical Terminology, 2nd ed. (the “Gold Book”) (1997). Online corrected version: (2006-) “Beer-Lambert law”. doi:10.1351/goldbook.B00626 ( Epub ahead of print).